Erica Daina

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3554009/publications.pdf

Version: 2024-02-01

37 papers	4,122 citations	331670 21 h-index	377865 34 g-index
37 all docs	37 docs citations	37 times ranked	4264 citing authors

#	Article	IF	Citations
1	Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1844-1859.	4.5	818
2	Why rare diseases are an important medical and social issue. Lancet, The, 2008, 371, 2039-2041.	13.7	457
3	Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Human Molecular Genetics, 2003, 12, 3385-3395.	2.9	291
4	Takayasu's arteritis: A study of 104 Italian patients. Arthritis and Rheumatism, 2005, 53, 100-107.	6.7	273
5	The Molecular Basis of Familial Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2001, 12, 297-307.	6.1	263
6	Interleukin-6 and RANTES in Takayasu Arteritis. Circulation, 1999, 100, 55-60.	1.6	216
7	Outcome of Renal Transplantation in Patients with Nonâ€“Shiga Toxinâ€“Associated Hemolytic Uremic Syndrome: Prognostic Significance of Genetic Background. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 88-99.	4.5	201
8	von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood, 2002, 100, 778-785.	1.4	200
9	Liver-Kidney Transplantation to Cure Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2009, 20, 940-949.	6.1	154
10	Eculizumab in a Patient with Dense-Deposit Disease. New England Journal of Medicine, 2012, 366, 1161-1163.	27.0	140
11	Outrageous prices of orphan drugs: a call for collaboration. Lancet, The, 2018, 392, 791-794.	13.7	132
12	Mycophenolate Mofetil for the Treatment of Takayasu Arteritis: Report of Three Cases. Annals of Internal Medicine, 1999, 130, 422.	3.9	129
13	Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Molecular Immunology, 2016, 71, 131-142.	2.2	126
14	Monogenic diseases that can be cured by liver transplantation. Journal of Hepatology, 2013, 59, 595-612.	3.7	111
15	Natural History and Outcome of Hepatic Vascular Malformations in a Large Cohort of Patients with Hereditary Hemorrhagic Teleangiectasia. Digestive Diseases and Sciences, 2011, 56, 2166-2178.	2.3	106
16	Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complexâ€“Mediated Membranoproliferative GN. Journal of the American Society of Nephrology: JASN, 2018, 29, 283-294.	6.1	89
17	Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thrombosis and Haemostasis, 2009, 101, 233-238.	3.4	85
18	Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood, 2005, 106, 925-928.	1.4	57

#	Article	IF	Citations
19	C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. American Journal of Kidney Diseases, 2019, 74, 224-238.	1.9	45
20	Rare Diseases in Europe: from a Wide to a Local Perspective. Israel Medical Association Journal, 2016, 18, 359-63.	0.1	45
21	Liver transplantation for aHUS: still needed in the eculizumab era?. Pediatric Nephrology, 2016, 31, 759-768.	1.7	22
22	Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. Kidney International, 1992, 42, 981-990.	5.2	21
23	Enzyme Replacement Therapy and Fabry Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 371-378.	4.5	21
24	Discordant phenotype in monozygotic twins with renal coloboma syndrome and a PAX2 mutation. Pediatric Nephrology, 2012, 27, 1989-1993.	1.7	19
25	The Italian National Rare Diseases Registry. Blood Transfusion, 2014, 12 Suppl 3, s606-13.	0.4	18
26	Urinary proteome signature of Renal Cysts and Diabetes syndrome in children. Scientific Reports, 2019, 9, 2225.	3.3	15
27	Biallelic variants in the ciliary gene TMEM67 cause RHYNS syndrome. European Journal of Human Genetics, 2018, 26, 1266-1271.	2.8	12
28	Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. Nephrology Dialysis Transplantation, 2023, 38, 283-290.	0.7	12
29	Left main stem patch plasty and aortic root homograft in Takayasu's disease. Annals of Thoracic Surgery, 2004, 77, 314-317.	1.3	9
30	A Multidrug, Antiproteinuric Approach to Alport Syndrome: A Ten-Year Cohort Study. Nephron, 2015, 130, 13-20.	1.8	9
31	Tackling the Problem of Rare Diseases in Public Health: The Italian Approach. Public Health Genomics, 2003, 6, 123-124.	1.0	8
32	CONFERENCE. Lancet, The, 1994, 343, 1560-1561.	13.7	7
33	Introduction: Hereditary Hemorrhagic Telangiectasia as a Rare Disease. Current Pharmaceutical Design, 2006, 12, 1171-1172.	1.9	7
34	Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation. Nephron, 2020, 144, 195-203.	1.8	4
35	Unravelling the pathophysiology of C3G/IC-MPGN and how to predict disease progression and orient therapies. Molecular Immunology, 2017, 89, 178.	2.2	0
36	Rare Autoimmune Diseases. Advances in Experimental Medicine and Biology, 2010, 686, 365-374.	1.6	0

#	Article	IF	Citations
37	Lupus Nephritis. , 0, , 244-252.		0